NeuTherapeutics

NeuTherapeutics is a clinical-stage biotechnology company with a dual focus on neurodegenerative diseases and women's brain health. Its lead asset, Allopregnanolone, is a regenerative therapy for Alzheimer's Disease currently in a Phase 2b trial (REGEN-BRAIN©), with the ambitious goal of halting or reversing disease progression. The company also markets PhytoSERM, a plant-based dietary supplement for menopausal symptoms, which provides an early revenue stream and aligns with its broader brain health mission. Operating as a private entity, NeuTherapeutics emphasizes precision medicine, rigorous clinical evidence, and patentable drug-delivery strategies to achieve its vision.

Strategic development approach focused on neurosteroids (allopregnanolone) for regenerative neurology and plant-based selective estrogen receptor modulators (SERMs) for women's brain health, supported by a data-driven clinical trial design philosophy.

In Alzheimer's, NeuTherapeutics faces intense competition from large pharma (e.g., Biogen, Eli Lilly) and biotechs targeting amyloid, tau, and inflammation. Its regenerative mechanism is a key differentiator. In women's health, PhytoSERM competes with numerous dietary supplements and a growing number of prescription therapies for vasomotor symptoms.